In a large prospective population-based cohort study of 2292 participants, the prevalence of NAFLD was 46.2% among patients with psoriasis, and even higher when compared to the prevalence among patients without psoriasis (33.3%), even after adjustment for alcohol use, alanine aminotransferase levels, and metabolic syndrome components [151]. This evidence concerns the gene GPT and metabolic dysfunction-associated steatotic liver disease.